Hyperhomocysteinemia is a risk factor for atherosclerosis, which may also be associated with retinal vascular disease, diabetic retinopathy, retinal vein occlusion, and glaucoma. For this study, we established a hyperhomocysteinemia animal model to explore homocysteine (hcy)-related choroidal angiogenesis and possible related factors. We injected Sprague Dawley (SD) rats with different concentrations of hcy and performed color fundus imaging, fluorescein angiography, image-guided optical coherence tomography, and retinal histology to observe the retinal and choroidal changes. Subsequently, we observed prominent choroidal vasculature with congested and tortuous retinal and choroidal vessels in fundus angiographies of the hyperhomocysteinemia animal model. In the histological study, the choroidal capillaries proliferated in the hcy-treated eyes, mimicking choroidal neovascularization. Disrupted retinal pigment epithelium (RPE), abnormal branching vascular network (BVN), and polyp-like structures were also observed in the hcy-treated eyes. Furthermore, we found that placental growth factor (PlGF), but not vascular epithelial growth factor (VEGF), was the key mediating factor of this phenomenon. Our findings suggest that hyperhomocysteinemia might cause choroidal angiogenesis.
. Hcy is usually formed when methionine is metabolized. It can be reprocessed into cysteine by cystathionine-beta-synthase or into methionine by methylene-tetrahydrofolate reductase (MTHFR) 13 . It is therefore patients with MTHFR mutation show hyperhomocysteinemia with different vascular disorders 13 . Apart from MTHFR defects, hyperhomocysteinemia may be possibly caused by diseases such as nephropathy 14 , psoriasis 15 , hypothyroidism 16 , diet problems such as vitamin B12 deficiency, folate deficiency, alcoholism, high intake of methionine 17 and medication such as nitrous oxide inhalation 18, 19 . However, the association between hcy and choroidal diseases is not widely reported. In developed countries, AMD accounts for more than 50% of vision loss in the elderly population. AMD can be categorized into dry and wet types. The wet type of AMD is associated with macular choroidal neovascularization (CNV), exudation, and hemorrhage 20 and affected patients may progressively develop metamorphopsia, central scotoma, or vision loss. Freund et al. proposed a more refined AMD classification into three types of neovascularization 21, 22 . Type I neovascularization is characterized by vessels proliferating beneath the retinal pigment epithelium (RPE), typically presenting as a fairly mature neovascularization that may have an incomplete response to anti-vascular endothelial growth factor (VEGF) therapy 22 . Polypoidal choroidal vasculopathy (PCV) is included in this classification as a variant of type 1 neovascularization. Conversely, type II neovascularization is characterized by the proliferation of neovascular tissue above the RPE, in the subretinal space, and it may have a Scientific REPORTS | (2018) 8:15755 | DOI:10.1038/s41598-018-34187-z complete response to anti-VEGF therapy 22 . Type III neovascularization is an intra-retinal neovascularization, also known as retinal angiomatous proliferation 23 . Although several effective therapies have been reported for these diseases, the possible mechanisms involved in these CNV diseases still require clarification.
Growth factors from the VEGF family control angiogenesis and increase vascular permeability in a number of eye diseases, including diabetic retinopathy and AMD 24 . Placental growth factor (PlGF) is also a member of the VEGF family. Both VEGF and PlGF play important roles in vessel sprouting and proliferation in the chorioretinal tissue 25 . Moreover, Klettner et al. reported that VEGF and PlGF were constitutively secreted and regulated by the RPE/choroid complex, with PlGF secreting mainly by the choroid 26 . VEGF receptor-1 (VEGFR-1) is a receptor for both PlGF and VEGF-A 24 . VEGFR-1 is reported to exist in pericytes and vascular smooth muscle cells rather than endothelial cells, suggesting the involvement of pericytes in the early phases of angiogenesis 24 . In addition, Inoue et al. reported that PlGF has a protective effect on retinal neurons and possibly other retinal cells 27 . Huo et al. discovered that inhibiting both VEGF and PlGF expression reduced neovascularization in a mouse model of laser-induced CNV 28 . All these studies have demonstrated that VEGF and PlGF play different roles in neovascularization development.
We previously reported that plasma hcy levels were significantly higher in patients with PCV than in those without PCV 29 , and we found that choroidal angiogenesis was facilitated by hcy in a choroidal capillary sprouting model 30 . Therefore, we assumed that hyperhomocysteinemia may play a role in type I CNV development, including PCV, possibly via an atherosclerosis pathway. In the current study, we investigated the possible characteristics of retinal cellular changes and choroidal vasculopathy in a hyperhomocysteinemia animal model.
Results
We obtained color fundus images, image-guided optical coherence tomography (OCT), and fluorescein angiography (FAG) results from hyperhomocysteinemia animals and examined the control animals to observe the chorioretinal vessel changes (Fig. 1 ). In the animals treated with 100 mg/kg hcy, we observed a dense and curly vessel distribution in the choroid layer of the fundus image (Fig. 1B ) compared with the control group (Fig. 1A) . Image-guided OCT results showed choroidal layer thickening (39 μm in Fig. 1D ) compared with the control group (26 μm in Fig. 1C ), and FAG results showed significant congestion and tortuosity of the retinal and choroidal vasculature (Fig. 1F ) compared with the control group (Fig. 1E) . A summary of choroidal thickness in OCT study was shown in Table 1 . An increase of mean choroidal thickness in the 100 mg/kg hcy-treated group was seen, but there was no statistical difference between groups.
Distributions of the retinal and choroidal vessels in animals treated with 30 mg/kg hcy and control animals were also evaluated on color fundus photography (for retinal vessels) and FAG (for both retinal and choroidal vessels). Figure 2 demonstrates the chorioretinal vasculature becoming more prominent and tortuous (Fig. 2C ) in the 30 mg/kg hcy-treated animals than in control animals ( Fig. 2A) . FAG imaging of the 30 mg/kg (Fig. 2D,F) and 60 mg/kg (Fig. 2H ) hcy-treated animals identified polyps in the choroid vessels but not in the retinal vessels (arrowhead in Figs. 2D,F,H). With light-pigmented RPE, FAG can depict the choroidal vessels of Sprague Dawley (SD) rats without the need for indocyanine green angiography. Visibility of this polyp only on FAG (Fig. 2D,F) but not on color fundus images (Fig. 2C,E ) of the same SD rat proves its existence in the choroidal layer of the hcy-treated animals. Furthermore, we observed that the polyp was beneath a crossing retinal vessel and located in the same level of nearby choroidal vessels (Fig. 2F) . The summary for FAG study was presented in Table 2 , which showed vessel tortuosity and statements for FAG features from control, 30, 60, 100 mg/kg hcy animals. The number of vessel tortuosity more than 1.33 was count in each FAG image and list in Table 2 . The original FAG images studied for Table 2 were presented in Supplementary Fig. 1 . There were notable tortuous retinal and choroidal vessels, congestive vessels, and polyps in hcy-treated animals. The result suggests that hyperhomocysteinemia may induce polyps in the choroidal layer, which is similar to the features of PCV.
We investigated the histological changes in the hcy-treated and control retinas using hematoxylin and eosin (H&E) staining and optical microscopy ( Fig. 3 ). An evenly distributed outer nuclear layer (ONL), inner nuclear layer (INL), outer segment (OS), choroid (Ch) and RPE was demonstrated with normal endothelial cells located in the choroid vessels in a chorioretinal section of a control animal (Fig. 3A) . Choroidal thickening was detected (Fig. 3B ) in the retinas of animals treated with 30 mg/kg hcy for 9 days, similar to pachychoroid in PCV patients. In addition, choroidal cell proliferation and neovascularization were identified (white arrow in Fig. 3C ) in animals treated with 10 mg/kg hcy for 9 days. Intra-Bruch's membrane (BM) cell proliferation in a curved pattern (Fig. 3D ) and neovascularization (white arrow in Fig. 3E ) were observed in the retinas of animals treated with 100 mg/kg hcy for 9 days (Fig. 3D,E) . We observed an abnormal branching vascular network (BVN) in an ovoid pattern (black arrowhead) and RPE disruption (white arrowhead) in the retinas of animals after recovering for 90 days following a 30 mg/kg hcy treatment for 9 days (Fig. 3F) . Polyps in different locations of the choroid were also observed in animals treated with 60 and 30 mg/kg hcy (Fig. 3G,H) , corresponding to the characteristics of PCV in the hyperhomocysteinemia animal model. Low-power microscopic images presenting retinal sections from different hcy-treated and control groups were presented in Supplementary Fig. 2 . Table 3 presents a summary of the histological characteristics of the animals treated with different concentrations of hcy in addition to details of the characteristics and the number of the animals. These histological studies indicate that hyperhomocysteinemia may lead to vascular endothelial cell proliferation and possibly neovascularization of the choroid.
The protein expression levels of angiopoietin1 (Ang1), angiopoietin2 (Ang2), platelet-derived growth factor B (PDGF-B), platelet-derived growth factor D (PDGF-D), VEGF, basic fibroblast growth factor (bFGF), and PlGF were evaluated in the chorioretinal tissue of different animals using Western blotting, and the results are shown in Figs 4 and 5. We examined the animals from the control, 1, 10, 30, and 100 mg/kg hcy-treated groups and found that PlGF expressions in animals treated with 30 and 100 mg/kg hcy were significantly upregulated compared with that in the control group (by 11.5-fold for PlGF monomer and 4.1-fold for total PlGF in 100 mg/kg hcy group, by 5.7-fold for PlGF dimer and 4.6-fold for total PlGF in 30 mg/kg hcy group; Fig. 5C and Supplementary Table 1 ), corresponding to increased immunofluorescence staining of the choroid as shown in Fig. 6 . The expression of VEGF appeared to increase slightly in the 100 mg/kg hcy-treated animals, but this was not statistically significant ( Fig. 5B , P = 0.072, compared to control group). The details of statistical analysis are displayed in Table 1 . Summary of choroidal thickness in OCT study. Choroidal thickness was measured from OCT images of each animal/eye. An increase of mean choroidal thickness in the 100 mg/kg hcy-treated group was seen, but there was no statistical significance between groups. One-way ANOVA was used to analyze the thickness, in which there was no significant difference between groups. In addition, there were no significant changes in the Ang1, Ang2, PDGF-B, and PDGF-D expression levels in these groups (Fig. 4B ). Using immunofluorescence staining, the retinal sections from the hyperhomocysteinemia animal model were continuously examined for the expression of various growth factors in the retinas (Fig. 6 ). In animals treated with or without hcy (Fig. 6A,B) , VEGF was expressed around the RPE-choroid area of the retinas. In comparison, PlGF was expressed only in the choroid area of the animals treated with hcy ( Fig. 6D ), but not in the control animals ( Fig. 6C ), suggesting that PlGF may play a key role in retinal and choroidal angiogenesis induced by hcy. Isolectin IB4 was also used to label the choroidal endothelial cells indicating location of vessels in control and hcy-treated eye (Fig. 6E,F) . A neovascularization at the RPE area and RPR disruption were noticed in the hcy-treated eye labeled with isolectin ( Fig. 6F ). In addition, we used two well-known anti-VEGFs, aflibercept and ranibizumab, subsequently to study possible factors involved in the chorioretinal vascularization with a choroidal capillary sprouting model. Aflibercept and ranibizumab are the two major anti-VEGFs used to treat diabetic retinopathy and neovascular AMD, including PCV 31 . Statistical results of the capillary sprouting area are shown in Fig. 7 . In total, 1 mM of hcy and 1 mg/mL of aflibercept or 0.25 mg/mL of ranibizumab was used in this study. Statistical data are presented in Table 4 . Addition of aflibercept to the hcy-treated chorioretinal explants inhibited the increase in the capillary sprouting area caused by hcy. However, ranibizumab did not indicate any similar inhibition effect on the hcy-treated preparations. The different effects caused by these two agents indicate that aflibercept may inhibit angiogenesis in the choroid caused by hcy, and this attributed to its unique feature that traps and blocks both VEGF and PlGF. However, ranibizumab blocks VEGF but not PlGF. We assume that PlGF upregulation might play a key role in hcy-induced chorioretinal vascularization. On the basis of the aforementioned results, we have determined that PlGF plays a key role in hcy-induced choroidal angiogenesis.
Discussion
Hcy is a sulfur-containing amino acid and metabolite of the essential amino acid methionine existing at a critical biochemical intersection in the methionine cycle 32 . The half-life of hcy in plasma is 223 ± 45 min (around 3.7 h) 33 , which suggests that the amount of hcy would reduce to 1.1% after 24 h. Consequently, we saw the pathological changes of the retina and choroid under high hcy concentrations (10-100 mg/kg) but not under low concentrations (1 mg/kg) in our animal model. A high serum level of hcy signals a breakdown in this vital process, which results in far-reaching biochemical and life consequences 32 . Hyperhomocysteinemia is related to small-vessel disease and atherosclerosis of the brain 2 and possibly vascular dementia and Alzheimer's disease 4, 5 . Previous studies have also suggested that hcy may be a risk factor for retinal vascular disease or a key factor in inducing retinal ganglion cell apoptosis 8, 34, 35 . A recent study suggests that hyperhomocysteinemia may possibly induce retinal endothelial cell dysfunction by activating oxidative stress in the endothelial cells 36 . Furthermore, we have reported that hyperhomocysteinemia was identified in PCV patients 29 . In our current study of a hyperhomocysteinemia animal model, choroidal cell proliferation, polyps, BVN, intra-BM cell proliferation, and neovascularization were observed in the microscopic study, suggesting that angiogenesis might progress in the presence of hyperhomocysteinemia. These histological findings were identified in those animals treated with 10, 30, 60, and 100 mg/kg hcy for 9 days, and some of the pathological changes persisted for 90 days following the hcy injection course. These histological findings are similar to the pathological features of type I CNV in humans 22 . Induced hyperhomocysteinemia in animals is similar to hyperhomocysteinemia in patients with PCV 29 . Because PCV is a variant of type I CNV, according to Freund et al., when combining these facts, this animal model might mimic human PCV in terms of choroidal angiogenesis 22 . Moreover, a thick choroid, a so-called pachychoroid, is associated with macular disease, e.g., PCV 37 . Pachychoroid is characterized by increased choroidal thickness and dilated choroidal vessels. In our hcy-injected rats, similar pictures were revealed on both OCT and chorioretinal histopathology, which suggests that hyperhomocysteinemia might cause chorioretinal cellular changes.
In wet AMD, upregulation of VEGF expression in the eye was considered to be related to CNV 38, 39 . CNV was thought to be a prominent feature of wet AMD 40 , and the suppression of VEGF expression was considered a possible solution for neovascularization in this type of disease 41, 42 . Clinically, CNV is commonly treated with an intravitreous injection of anti-VEGF antibody. Hence, we investigated the expression levels of different types of VEGFs in this study, revealing that VEGF was detected in the choroid of the eyes of both the control and hyperhomocysteinemia animals; however, PlGF was detected in the choroid of the eyes of only the hyperhomocysteinemia animals. In this study, aflibercept and ranibizumab were used to investigate the possible mechanisms associated with hcy-induced choroid vessel sprouting. Clinically, aflibercept has potent therapeutic effects on neovascular AMD and retinal vascular diseases 43, 44 . With regard to PCV treatment, aflibercept is more effective than ranibizumab 31, 45, 46 . These two drugs differ in terms of structure and mechanism. Ranibizumab, a monoclonal antibody ; hence, it only suppresses the activation of VEGFR-1. Aflibercept, a recombinant fusion protein with combined VEGFR-1 and VEGFR-2 binding domains 48 , effectively inhibits the effects of both VEGF-A and PlGF. Our results showed that aflibercept inhibited hcy-evoked capillary sprouting, whereas ranibizumab did not. This suggests PlGF may play a key role in hcy-induced chorioretinal vascularization.
Moreover, we investigated the expression of other angiogenesis-related growth factors, such as Ang1, Ang2, PDGF-B, and PDGF-D, of the retinal and choroidal preparations from both the control and hcy-treated animals. Angiopoietins are proteins involved in vascular development and angiogenesis. For instance, Ang1 promotes endothelial cell sprouting and tube formation 49 , whereas Ang2 regulates angiogenesis and endothelial inflammation 50 . In addition to angiopoietins, PDGFs are important in the development of connecting tissues, including endothelial and epithelial cells 51 . However, expressions of angiopoietins and PDGFs were not found to be altered in the different groups in this study. Our findings suggest that PlGF may be upregulated by hyperhomocysteinemia and may play a role in choroidal vessel proliferation in this animal model. PlGF is a member of the VEGF family but it binds to different VEGF receptor subtypes. Inoue et al. reported that PlGF has a protective effect on retinal neurons and possibly other retinal cells 27 . Kowalczuk et al. also reported that tortuous and dilated capillaries were observed in a PlGF over-expression animal model 52 , which is similar to our findings in FAG study of the hcy-treated animals. In this hyperhomocysteinemia animal model, we found that the presence of hcy considerably enhanced PlGF expression; PlGF was significantly increased in the RPE and choroid layers, but VEGF was slightly increased; thus, we suggest that PlGF may play a key role in hcy-induced choroidal angiogenesis.
We conclude that hyperhomocysteinemia caused retinal cellular changes and choroidal angiogenesis, which may be related to hcy-induced atherosclerosis. An upregulation of PlGF was also observed in the hyperhomocysteinemia animals. Our hyperhomocysteinemia animal model demonstrates pathological features similar to type I CNV, which corresponds to hyperhomocysteinemia in patients with clinical PCV.
Materials and Methods
Animal Model of Hyperhomocysteinemia. SD rats (250-300 g, male, from BioLASCO Technology, Taipei, Taiwan) were maintained in a normal light environment of 100 lux. All animal protocols were conducted in accordance with the Statement for Committee of Fu-Jen Catholic University and Taipei Veterans General Hospital. The hyperhomocysteinemia animal model was generated by the intravenous administration of various doses of hcy through the tail veins of the animals. The animals received 1, 10, 30, 60, or 100 mg/kg of hcy once a day for 9 consecutive days. In the control group, normal saline (0.9%) was administered instead of hcy. The animals were euthanized 1 day after completion of the injection course, and both eyes were collected for histological and immunohistochemical examinations as well as a protein expression assay. Several rats from the 30 mg/kg group were kept for another 90 days of recovery after the 9-day injection course and were subsequently euthanized, and the eyes were collected for histological examination.
Fundus Images. One day after completion of the intravenous injection course, fundus images were obtained in both groups to compare the chorioretinal vascular changes. The procedure for obtaining fundus images is briefly described as follows. During the examinations, the animals were sedated with Zoletil (40 mg/kg; Virbac SA, Carros, France). Their pupils were dilated with 1.0% tropicamide (Alcon, Fort Worth, TX, USA), and the corneas were locally anesthetized with 0.5% proparacaine (Alcon). A retinal imaging microscope system (Micron IV, Phoenix Research Labs, Pleasanton, CA, USA) was utilized for color fundus photography, FAG, and image-guided OCT. The tortuosity of retinal and choroidal vessels in FAG images were analyzed via MatLab (The MathWorks, Inc. Natick, MA, USA) with ARIA (Automated Retinal Image Analyzer, Copyright 2011 Peter Bankhead) implements the vessel detection and tortuosity measurement 53 , in which vessel tortuosity measure is defined as the vessel segment length divided by the Euclidean distance between the vessel segment end points. Number of vessel tortuosity more than 1.33 was counted and presented in Table 2 .
Histological Analysis of the Retina and Choroid. The histologies of the retinal and choroidal vessels were examined using H&E staining. The eyes obtained from rats treated with different preparations were embedded in a tissue-freezing medium and frozen at −80 °C. The eyes were immersed in a fixative solution containing 4% paraformaldehyde in phosphate-buffered saline (pH 7.4) and cut into 5-μm-thick sections using a cryostat (CM3050 S, Leica, Wetzlar, Germany). These sections were stained with hematoxylin (Muto Pure Chemicals Co., Ltd., Tokyo, Japan) and eosin Y (Thermo Fisher Scientific, Kalamazoo, MI, USA) and mounted with HistoMount Immunofluorescence Staining. Immunofluorescence staining was performed on the eye sections of the animals to examine the location and expression of different types of VEGFs, and the eyes were collected following euthanasia and cryostat-sectioned at 5 μm thickness. Each section was mounted on a slide and prepared for immunohistochemical staining. Anti-VEGF and anti-PlGF were used as the primary antibodies, and Alexa 488 (A11055, Molecular Probes, Life Technologies, Grand Island, NY, USA) and Alexa 555 (A31572, Molecular Probes) were used as the secondary antibodies. Isolectin IB4 conjugated Alexa 594 (121413, Molecular Probes, Life Technologies, Grand Island, NY, USA) was used to stain the endothelial cells. Cell nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI, sc-3598, Santa Cruz Biotechnology). An upright fluorescence microscope (DM2500, Leica) with a cooled Charge-coupled Device (CCD) camera system (CoolSNAP EZ, Roper Scientific, Martinsried, Germany) was used to observe epifluorescence expression of the retinal sections.
Choroidal capillary sprouting assay. The choroidal capillary sprouting model was adapted from the study of Shao et al. with minor modifications 54 . We used both female and male C57BL/6 mice aged 8-12 weeks (BioLASCO Taiwan, Taipei, Taiwan). All animal experiments were conducted in accordance with the Statement for the Use of Animals in Ophthalmic and Vision Research of the Association for Research in Vision and Ophthalmology, and approved by the Institutional Animal Care and Use Committee of Fu-Jen Catholic University. The chorioretinal fragments (retina, RPE layer, and choroid) obtained from the animals were isolated, mounted with Matrigel (Sigma-Aldrich Corp., St Louis, MO, the USA), and seeded in 24-well culture plates. The choroidal tissue was incubated in cell systems complete classic medium (Cat. no.: 420-500; Cell Systems, Kirkland, WA, the USA) with or without hcy (1 mM). The culture medium was changed daily for 5 consecutive days. The area within the circle that connects the outer ends of the choroidal capillary sprouts from each choroidal explant was measured every 24 h for 5 days (120 h). In some preparations, aflibercept (1 mg/mL; Bayer, Leverkusen, Germany) or ranibizumab (0.25 mg/mL; Novartis, Basel, Switzerland) were added to the medium with or without hcy (1 mM) to evaluate their effects. Images were acquired using a stereomicroscope (Leica M165FC, Wetzlar, Germany) and a digital camera (Leica DFC310FX, Wetzlar, Germany) at each time point.
Statistical Analysis. Data from protein expressions were analyzed using SPSS Statistics, version 20 software (IBM, Armonk, New York, USA), and statistical analysis was performed to determine protein expression differences between the groups. One-way ANOVA with Dunnett's test or LSD for multiple comparisons was used to determine the significance of the differences between the groups. Differences were considered to be statistically significant when P < 0.05.
